Skip to content

Study · Animal study (in vivo) · rat · 2014

1 result

[Effects of neonatal fluvoxamine administration to white rats and their correction by semax treatment].

Volodina MA, Merchieva SA, Sebentsova EA, Glazova NIu, Manchenko DM, Andreeva LA, Levickaia NG, Kamenskiĭ AA, Miasoedov NF

Izvestiia Akademii nauk. Seriia biologicheskaia1 Jul 2014Cited by 1 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats given fluvoxamine as pups, which delayed growth, reduced body weight, raised anxiety and disturbed learning, semax treatment largely compensated these negative consequences.

    In plain wordsIn rats given fluvoxamine as pups, semax treatment largely offset the later growth, weight, anxiety and learning problems.

    Peptide
    Semax
    Outcome
    MixedCorrection of neonatal fluvoxamine effects (growth, body weight, anxiety, learning)
    Study

    ratn: not reported in source

    Neonatal fluvoxamine administration (postnatal days 1-14)
    Outcome group
    Overall treatment effect · Nervous system and cognition
    Studied dose
    0.05 mg/kg · intranasal · postnatal days 15 to 28As given in this study (rat).

    Source sentences

    Summary
    The negative consequences of neonatal FA administration were largely compensated by Semax.
    2 context sentences
    Summary · context
    Furthermore, FA administration increased the anxiety level and disturbed the learning ability of animals.
    Summary · context
    Fluvoxamine was injected intraperitoneally at a dose of 10 mg/kg from postnatal days 1 to 14, and semax was injected intranasally at a dose of 0.05 mg/kg from postnatal days 15 to 28.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 17:28 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.